Permira has completed the sale of portfolio company Arysta LifeScience to Platform Specialty Products for $3.51 billion. The transaction consisted of $2.91 billion in cash along with $600 million in Series B convertible preferred stock. Operating in more than 125 countries, Arysta is a provider of crop protection and life science products. Barclays, Credit Suisse, UBS and Nomura Securities committed financing for the acquisition. Permira had backed Arysta since 2008.